GE Healthcare announced a manufacturing agreement with Advanced Accelerator Applications (AAA), an international player in molecular nuclear medicine. In combination with GE Healthcare’s existing TracerNET network the new partnership will provide additional capability of proprietary PET tracer production to a cumulative total of 20 sites and initial coverage in 11 countries. This agreement is GE Healthcare’s first step toward establishing a pan-European PET distribution network over the next few years.
“GE Healthcare has a global commitment to advancing clinical knowledge and providing innovations that transform patient management. It is key to ensure new PET tracers availability broadly,” said Jonathan Allis, MI PET General Manager, GE Healthcare Medical Diagnostics. “Molecular imaging plays an important role in enabling confident medical decisions and is the basis of our business.”
Currently, there are 15 tracers in various stages of development in GE Healthcare’s PET portfolio.
AAA is one of Europe’s leading independent third-party manufacturers of PET products. “We believe this agreement represents an important opportunity to accelerate our development plan of PET manufacturing facilities throughout Europe and it has the potential to become our widest offering PET registered manufacturing in Europe,” said Stefano Buono President and CEO of AAA.